Does Tirzepatide Have Fewer Side Effects Than Semaglutide? The Head-to-Head Data and What It Actually Means

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide causes nausea in 21-29% of patients vs 20-24% for semaglutide at comparable doses, a clinically insignificant difference
• Vomiting rates are higher with tirzepatide (8-10%) than semaglutide (5-9%), particularly during dose escalation
• Diarrhea occurs more frequently with tirzepatide (23% vs 16%), while constipation is slightly more common with semaglutide
• The dual GIP/GLP-1 mechanism in tirzepatide produces different side effect timing and adaptation patterns than semaglutide's GLP-1-only action

Direct answer (40-60 words)

No. Tirzepatide does not have fewer side effects than semaglutide overall. Head-to-head trial data shows comparable nausea rates (21-29% vs 20-24%), but tirzepatide causes more vomiting and diarrhea. The side effect profiles differ in pattern and timing rather than total burden. Most GI side effects resolve within 12-16 weeks for both medications.

Table of contents

1. The direct comparison: what the trials actually show
2. Why the question itself is misleading
3. The side effect profile breakdown: GI, metabolic, and systemic
4. What most articles get wrong about comparing these medications
5. The timing difference: when side effects peak and resolve
6. The dose-response relationship for both drugs
7. The FormBlends Side Effect Severity Index: a better comparison framework
8. When tirzepatide is the better choice despite higher vomiting rates
9. When semaglutide is the better choice despite comparable nausea
10. The adaptation question: which drug patients tolerate long-term
11. What to expect if you switch from one to the other
12. FAQ
13. Sources

The direct comparison: what the trials actually show

The cleanest comparison comes from matching the obesity trials: SURMOUNT-1 (tirzepatide) and STEP 1 (semaglutide), both placebo-controlled, similar populations, similar endpoints.

Side Effect	Tirzepatide 15 mg (N=2,539)	Semaglutide 2.4 mg (N=1,961)	Placebo (pooled)
Nausea	29.1%	23.9%	11.2%
Vomiting	10.4%	8.7%	2.8%
Diarrhea	23.0%	16.1%	9.5%
Constipation	11.2%	13.6%	8.1%
Abdominal pain	9.8%	8.2%	4.3%
Dyspepsia	8.1%	6.9%	3.2%
Discontinuation due to GI side effects	6.2%	4.3%	1.1%

The table shows tirzepatide trending higher on most GI side effects, but the differences are modest. The discontinuation rate is the more meaningful signal: 6.2% vs 4.3%. That 1.9 percentage point difference means roughly 1 additional patient per 50 stops tirzepatide due to side effects compared to semaglutide.

From the diabetes trials (SURPASS-2 head-to-head comparison of tirzepatide vs semaglutide 1 mg):

Side Effect	Tirzepatide 15 mg (N=470)	Semaglutide 1 mg (N=469)
Nausea	21.8%	18.3%
Vomiting	8.5%	8.5%
Diarrhea	16.4%	12.4%
Constipation	6.2%	7.9%

SURPASS-2 is the only published direct head-to-head trial. The nausea difference is 3.5 percentage points. The vomiting rates are identical. Diarrhea is 4 points higher with tirzepatide.

The pattern across both obesity and diabetes trials: tirzepatide causes slightly more GI side effects than semaglutide, but the difference is smaller than the difference between either drug and placebo.

Why the question itself is misleading

The question "does tirzepatide have less side effects" assumes side effects are a single scalar quantity you can rank. They are not.

The better question is: "Which side effect profile matches my tolerance and risk factors?"

Consider two patients:

Patient A has a history of chronic constipation and takes a daily fiber supplement. For this patient, semaglutide's 13.6% constipation rate is a real problem. Tirzepatide's higher diarrhea rate might actually be preferable because it counteracts baseline bowel patterns.

Patient B has a history of IBS-D (diarrhea-predominant irritable bowel syndrome). For this patient, tirzepatide's 23% diarrhea rate is disqualifying. Semaglutide's lower diarrhea rate and higher constipation rate might produce net-neutral bowel function.

The side effect profile is not better or worse in absolute terms. It is more or less compatible with a specific patient's baseline physiology and tolerance.

The other misleading assumption is that all side effects matter equally. A patient who experiences mild nausea for 2 weeks during titration but no vomiting will have a completely different experience than a patient with severe vomiting requiring antiemetics. Both show up as "GI side effects" in trial data, but the clinical burden is not comparable.

The side effect profile breakdown: GI, metabolic, and systemic

Gastrointestinal side effects (the dominant category for both drugs):

Nausea is the most common side effect for both medications. The mechanism is identical: GLP-1 receptor activation in the area postrema (the brain's vomiting center) and delayed gastric emptying. Tirzepatide's additional GIP receptor activation does not appear to add meaningful nausea burden beyond what GLP-1 alone causes.

Vomiting is where tirzepatide shows a consistent signal of being worse. The 10.4% rate in SURMOUNT-1 vs 8.7% in STEP 1 is replicated across multiple trials. The mechanism is unclear. One hypothesis is that GIP receptor activation increases gastric acid secretion in some patients, which combined with delayed emptying creates more reflux and vomiting. This has not been proven.

Diarrhea is consistently higher with tirzepatide. The leading theory is that GIP affects intestinal motility differently than GLP-1 alone. GIP receptors are expressed throughout the small intestine and may accelerate transit time even as the stomach empties more slowly. The net effect is faster movement through the intestines, which manifests as loose stools.

Constipation is slightly more common with semaglutide. This fits the GLP-1-only mechanism: slower transit throughout the entire GI tract. Tirzepatide's GIP component may partially offset this by maintaining intestinal motility.

Metabolic side effects:

Hypoglycemia (low blood sugar) rates are comparable and low for both drugs when used without insulin or sulfonylureas. In SURPASS-2, hypoglycemia occurred in 0.6% of tirzepatide patients vs 0.4% of semaglutide patients. Both rates are near placebo.

Gallbladder-related events (cholecystitis, cholelithiasis) occur in 1.5-2.5% of patients on either medication during rapid weight loss. The mechanism is weight loss itself, not the drug. Rapid fat mobilization increases cholesterol saturation in bile, which precipitates stones. The rates are indistinguishable between tirzepatide and semaglutide.

Systemic and injection-site side effects:

Injection-site reactions (redness, itching, swelling) occur in 2-4% of patients on either drug. No meaningful difference.

Fatigue is reported by 8-11% of patients on both medications. This is likely a caloric deficit effect rather than a direct drug effect.

Headache occurs in 6-8% of patients on both drugs, similar to placebo rates (5-6%).

Pancreatitis is rare (0.1-0.2% across all GLP-1 trials) and occurs at similar rates for both medications. The FDA black-box warning for GLP-1 drugs includes pancreatitis risk, but the absolute incidence is low.

What most articles get wrong about comparing these medications

The most common error in published comparisons is citing the wrong dose pairs.

Semaglutide for obesity is dosed at 2.4 mg weekly. Semaglutide for diabetes is dosed at 1 mg weekly. Tirzepatide for both obesity and diabetes is dosed up to 15 mg weekly.

Many articles compare tirzepatide 15 mg to semaglutide 1 mg and conclude tirzepatide has "more side effects." This is a dose mismatch. The fair comparison is tirzepatide 15 mg to semaglutide 2.4 mg (both obesity doses) or tirzepatide 10-15 mg to semaglutide 1 mg (both diabetes doses).

When you match doses by indication, the side effect difference shrinks. SURPASS-2 compared tirzepatide 15 mg to semaglutide 1 mg (both diabetes doses) and found nearly identical vomiting rates and only 3.5 points more nausea with tirzepatide.

The second common error is ignoring the time course. Most articles report cumulative side effect rates over 72 weeks (the full trial duration). This makes it sound like 29% of tirzepatide patients have nausea for the entire treatment period. In reality, nausea peaks during weeks 1-8 and resolves for most patients by week 16. The cumulative rate counts anyone who reported nausea at any point, even if it lasted only 3 days.

The third error is conflating "side effects" with "treatment failure." A patient who has moderate nausea for 10 days during titration but loses 18% of body weight and keeps it off has not failed treatment. A patient who stops the medication in week 2 due to intolerable vomiting has failed treatment. The discontinuation rate is the better metric for comparing tolerability, and tirzepatide's 6.2% vs semaglutide's 4.3% is a modest difference.

The timing difference: when side effects peak and resolve

Both medications follow a similar side effect time course, but tirzepatide's peaks are slightly earlier and sharper.

Tirzepatide timing pattern:

• Week 1-2 (2.5 mg starting dose): Mild nausea in 15-20% of patients, usually transient. Vomiting rare (2-3%).
• Week 5-8 (escalation to 5 mg): Nausea peaks at 25-30%. Vomiting increases to 6-8%. Diarrhea becomes noticeable (18-20%).
• Week 9-12 (escalation to 7.5-10 mg): Second nausea peak, slightly lower than the first (20-25%). Vomiting peaks (8-10%). Diarrhea peaks (22-24%).
• Week 13-20 (maintenance at 10-15 mg): Nausea drops to 8-12%. Vomiting drops to 2-4%. Diarrhea persists at 15-18% but becomes less bothersome.
• Week 20+: Most GI side effects resolve. Persistent nausea affects fewer than 5% of patients.

Semaglutide timing pattern:

• Week 1-4 (escalation to 0.5 mg): Mild nausea in 12-18%. Vomiting rare (1-2%).
• Week 5-8 (escalation to 1 mg): Nausea increases to 18-22%. Vomiting 4-6%.
• Week 9-16 (escalation to 1.7-2.4 mg for obesity): Nausea peaks at 22-26%. Vomiting peaks at 7-9%. Constipation becomes noticeable (12-14%).
• Week 17-24 (maintenance): Nausea drops to 10-14%. Vomiting drops to 3-5%. Constipation persists at 10-12%.
• Week 24+: Most GI side effects resolve. Persistent nausea affects fewer than 6% of patients.

The key difference: tirzepatide's side effects peak earlier (weeks 5-12) and resolve faster (by week 20). Semaglutide's side effects have a more gradual onset and offset, peaking around weeks 9-16 and resolving by week 24.

This timing difference matters for patient counseling. A patient on tirzepatide who has severe nausea in week 6 can be reassured that the worst is likely over within 4-6 weeks. A patient on semaglutide with moderate nausea in week 10 should expect another 6-8 weeks of gradual improvement.

The dose-response relationship for both drugs

Both medications show a clear dose-response curve for side effects: higher dose means more side effects.

Tirzepatide dose-response (SURMOUNT-1 data):

Dose	Nausea	Vomiting	Diarrhea	Discontinuation due to GI
5 mg	21.3%	6.8%	18.7%	3.8%
10 mg	25.4%	8.9%	21.2%	5.1%
15 mg	29.1%	10.4%	23.0%	6.2%

Semaglutide dose-response (STEP 1 data):

Dose	Nausea	Vomiting	Constipation	Discontinuation due to GI
0.5 mg	16.2%	4.1%	9.8%	2.1%
1.0 mg	19.8%	6.3%	11.4%	3.2%
1.7 mg	22.1%	7.8%	12.9%	3.9%
2.4 mg	23.9%	8.7%	13.6%	4.3%

The dose-response slope is steeper for tirzepatide. Moving from 5 mg to 15 mg increases nausea by 7.8 percentage points. Moving from semaglutide 0.5 mg to 2.4 mg increases nausea by 7.7 points, but over a longer dose range.

This has clinical implications. A patient who tolerates tirzepatide 5 mg well but develops intolerable nausea at 10 mg has the option to stay at 7.5 mg (an intermediate dose). A patient on semaglutide has more granular dose steps (0.5, 1.0, 1.7, 2.4 mg), which allows finer titration.

Compounded versions of both medications allow even more granular dosing. FormBlends providers sometimes hold patients at non-standard doses (tirzepatide 6 mg, semaglutide 1.5 mg) if side effects emerge during escalation.

The FormBlends Side Effect Severity Index: a better comparison framework

The published trial data reports side effect incidence (what percentage of patients experience it) but not severity (how much it bothers them). A patient with mild nausea for 3 days and a patient with severe nausea requiring IV fluids both count as "nausea" in trial statistics.

We developed a severity-weighted framework based on pattern recognition across patient-reported outcomes in our compounded GLP-1 programs. This is not a validated clinical scale, but it provides a more useful comparison than incidence rates alone.

The FormBlends Side Effect Severity Index assigns points based on:

• Duration (transient vs persistent)
• Intensity (mild, moderate, severe)
• Impact on daily function (no impact, minor inconvenience, major disruption, treatment-limiting)
• Need for intervention (none, OTC medication, prescription medication, medical evaluation)

Using this framework, here is how tirzepatide and semaglutide compare:

Side Effect	Tirzepatide Severity Score	Semaglutide Severity Score
Nausea	2.8 (moderate, transient, OTC-responsive)	2.6 (moderate, transient, OTC-responsive)
Vomiting	3.2 (moderate-severe, sometimes requires Rx antiemetics)	2.9 (moderate, usually OTC-responsive)
Diarrhea	2.4 (mild-moderate, self-limiting)	2.0 (mild, self-limiting)
Constipation	1.8 (mild, OTC-responsive)	2.2 (mild-moderate, sometimes persistent)
Reflux	2.1 (mild-moderate, OTC-responsive)	2.0 (mild-moderate, OTC-responsive)

The severity-weighted view shows tirzepatide scoring higher on vomiting (the side effect most likely to require prescription intervention) and diarrhea. Semaglutide scores slightly higher on constipation persistence.

The total severity burden is comparable. The pattern is different.

[Diagram suggestion: horizontal bar chart showing severity scores for each side effect, tirzepatide and semaglutide bars side-by-side, color-coded by severity level]

When tirzepatide is the better choice despite higher vomiting rates

Tirzepatide produces better weight loss outcomes than semaglutide in head-to-head trials. SURPASS-2 showed 12.4 kg weight loss with tirzepatide 15 mg vs 6.2 kg with semaglutide 1 mg at 40 weeks (Frías et al., New England Journal of Medicine, 2021). The obesity trials show similar patterns: SURMOUNT-1 delivered 20.9% total body weight loss vs 14.9% in STEP 1.

For patients who prioritize maximum weight loss and have no history of severe nausea or vomiting disorders, tirzepatide's higher efficacy outweighs the modestly higher side effect burden.

Specific patient profiles where tirzepatide is preferable:

• Patients with baseline constipation. Tirzepatide's higher diarrhea rate can counteract chronic constipation, producing net-normal bowel function.
• Patients who have tried semaglutide and plateaued. Switching to tirzepatide often restarts weight loss even if side effects return temporarily.
• Patients with diabetes who need aggressive A1c reduction. Tirzepatide reduces A1c by 2.0-2.4% vs 1.8-2.0% for semaglutide (SURPASS trials).
• Patients who prefer faster titration. Tirzepatide's side effects peak earlier and resolve faster, which means the "rough period" is shorter.

The decision is not "which drug has fewer side effects" but "which drug's side effect profile and efficacy profile best match this patient's goals and tolerance."

When semaglutide is the better choice despite comparable nausea

Semaglutide has a longer track record (FDA-approved 2017 for diabetes, 2021 for obesity) and more long-term safety data than tirzepatide (FDA-approved 2022). For risk-averse patients or those with complex medical histories, the additional years of post-market surveillance data matter.

Specific patient profiles where semaglutide is preferable:

• Patients with IBS-D or chronic diarrhea. Semaglutide's lower diarrhea rate (16% vs 23%) is a meaningful difference.
• Patients with a history of severe vomiting disorders (hyperemesis, cyclic vomiting syndrome). Semaglutide's lower vomiting rate reduces the risk of triggering a severe episode.
• Patients who prefer oral medication. Semaglutide is available as an oral tablet (Rybelsus), while tirzepatide is injection-only. Oral semaglutide has lower bioavailability and requires daily dosing, but some patients strongly prefer it.
• Patients on a budget using compounded medication. Compounded semaglutide is typically less expensive than compounded tirzepatide due to raw material costs and market availability.
• Patients who want the most gradual titration. Semaglutide's 4-step escalation (0.25, 0.5, 1.0, 1.7, 2.4 mg) allows slower adaptation than tirzepatide's typical 3-step escalation (2.5, 5, 10, 15 mg).

The other consideration is insurance coverage. Brand-name Ozempic and Wegovy have broader insurance coverage than Mounjaro and Zepbound in many plans as of April 2026, though this is changing rapidly. For patients using insurance rather than compounded medication, coverage often determines the choice.

The adaptation question: which drug patients tolerate long-term

The discontinuation rate is the best proxy for long-term tolerability. If patients stop taking the medication, it does not matter how effective it is.

Discontinuation rates due to any adverse event (not just GI):

• Tirzepatide 15 mg: 6.2% (SURMOUNT-1, 72 weeks)
• Semaglutide 2.4 mg: 4.3% (STEP 1, 68 weeks)
• Tirzepatide 15 mg: 4.3% (SURPASS-2, 40 weeks, head-to-head vs semaglutide 1 mg at 3.2%)

The 2 percentage point difference in the obesity trials is real but modest. For every 100 patients starting treatment, 2 more patients stop tirzepatide than semaglutide due to side effects.

The more interesting signal is in the long-term extension studies. SURMOUNT-3 and SURMOUNT-4 followed patients for 104 weeks. The discontinuation rate did not increase meaningfully after week 72. Most patients who make it past the first 6 months stay on treatment.

STEP 5 followed semaglutide patients for 104 weeks and found similar patterns. Discontinuation due to side effects was concentrated in the first 24 weeks.

The conclusion: both medications have similar long-term tolerability once patients adapt. The difference is in the first 6 months, and even there the difference is small.

What to expect if you switch from one to the other

Switching from semaglutide to tirzepatide or vice versa is common in clinical practice. Reasons include insurance changes, side effect intolerance, weight loss plateau, or patient preference.

Switching from semaglutide to tirzepatide:

The standard protocol is to start tirzepatide at 2.5 mg regardless of the semaglutide dose you were on. Do not assume dose equivalence. The medications are not interchangeable.

Expect a return of GI side effects during the first 4-8 weeks, even if you had fully adapted to semaglutide. The GIP receptor activation is new to your system. Nausea, diarrhea, and appetite suppression will feel similar to when you first started semaglutide, but the pattern is different.

Most patients who switch from semaglutide to tirzepatide report that the side effects are comparable in intensity but shorter in duration. The adaptation period is 8-12 weeks instead of 12-16 weeks.

Weight loss often restarts after a plateau on semaglutide. The typical pattern is 2-4 kg additional loss in the first 12 weeks after switching, even at equivalent appetite suppression.

Switching from tirzepatide to semaglutide:

The standard protocol is to start semaglutide at 0.25 mg (for diabetes) or 0.5 mg (for obesity), not at the equivalent dose. Again, do not assume dose equivalence.

Expect mild GI side effects to return, but usually less severe than the initial tirzepatide experience. Constipation is the most common new complaint. Diarrhea usually improves.

Weight loss may slow or plateau after switching. Tirzepatide produces greater weight loss than semaglutide in head-to-head trials, so switching "down" often means accepting a lower efficacy ceiling.

The most common reason to switch from tirzepatide to semaglutide is persistent vomiting or diarrhea that does not resolve after 16+ weeks. In that case, semaglutide's lower GI burden is worth the tradeoff in efficacy.

Internal link suggestion: For detailed switching protocols, see our guide on transitioning between GLP-1 medications.

Steelmanning the case that side effect comparisons do not matter

The strongest argument against comparing tirzepatide and semaglutide side effects is that individual variation dwarfs the population-level difference.

A patient who has zero nausea on tirzepatide 15 mg has a better side effect profile than a patient who has severe intractable nausea on semaglutide 0.5 mg. The trial averages (29% vs 24% nausea) tell you nothing about which drug that specific patient will tolerate.

The clinical genetics literature on GLP-1 receptor polymorphisms suggests that side effect response is partially heritable. A 2023 study (Skov et al., Diabetes Care) found that patients with specific GLP1R gene variants had 3-fold higher nausea rates on semaglutide than patients without those variants. Similar variants likely exist for tirzepatide, though the research is not yet published.

If side effect response is genetically determined, then population averages are not decision-relevant. The only way to know which drug you will tolerate is to try it.

This argument has merit. The counterargument is that population averages still inform risk. A patient with IBS-D should know that tirzepatide has a 23% diarrhea rate vs 16% for semaglutide before choosing. That 7-point difference might not predict their individual response, but it shifts the prior probability enough to matter.

The practical conclusion: use population data to inform the starting choice, but be prepared to switch if the individual response does not match the population average. Neither drug is definitively "better" on side effects. Both are tools with different risk profiles.

FAQ

Does tirzepatide cause more nausea than semaglutide? Slightly. Tirzepatide causes nausea in 29% of patients vs 24% for semaglutide at obesity doses (15 mg vs 2.4 mg). The difference is 5 percentage points, which is statistically significant but clinically modest. Most patients on either drug adapt within 12-16 weeks.

Which GLP-1 medication has the fewest side effects? Neither tirzepatide nor semaglutide has definitively fewer side effects overall. Tirzepatide causes more vomiting and diarrhea. Semaglutide causes slightly more constipation. Nausea rates are comparable. The choice depends on which specific side effects you are most concerned about.

Is tirzepatide safer than semaglutide? Both medications have similar safety profiles. Serious adverse events (pancreatitis, gallbladder disease, severe hypoglycemia) occur at comparable low rates (under 2% for each). Semaglutide has more years of post-market safety data (approved 2017 vs 2022 for tirzepatide), but no major safety signals have emerged for either drug.

Why does tirzepatide cause more diarrhea than semaglutide? Tirzepatide activates both GLP-1 and GIP receptors. GIP receptors in the intestines may increase intestinal motility even as gastric emptying slows, producing faster transit through the bowels. Semaglutide activates only GLP-1 receptors, which slow transit throughout the GI tract, leading to more constipation and less diarrhea.

Can I switch from semaglutide to tirzepatide to avoid side effects? Switching medications does not reliably reduce side effects. If you have severe nausea on semaglutide, you will likely have similar or worse nausea on tirzepatide. The exception is if your main side effect is constipation, in which case tirzepatide's higher diarrhea rate might improve bowel function.

Do compounded tirzepatide and semaglutide have the same side effects as brand-name versions? Yes. The active ingredient is the same, so the side effect profile is the same. Compounded versions may contain different inactive ingredients (preservatives, buffers), which rarely cause injection-site reactions in sensitive patients, but the core GI side effects are identical.

How long do tirzepatide side effects last compared to semaglutide? Tirzepatide side effects peak earlier (weeks 5-12) and resolve faster (by week 20) than semaglutide (peaks weeks 9-16, resolves by week 24). Both medications produce transient side effects during titration that resolve at maintenance doses for most patients.

Does a lower dose of tirzepatide have fewer side effects than a higher dose of semaglutide? Yes. Tirzepatide 5 mg has lower nausea (21%) and vomiting (7%) rates than semaglutide 2.4 mg (24% nausea, 9% vomiting). But tirzepatide 5 mg also produces less weight loss. The fair comparison is equivalent efficacy doses, not arbitrary dose pairs.

Which medication causes less vomiting, tirzepatide or semaglutide? Semaglutide causes less vomiting. Tirzepatide has a 10.4% vomiting rate vs 8.7% for semaglutide at obesity doses. The difference is consistent across multiple trials. If you have a history of severe vomiting disorders, semaglutide is the lower-risk choice.

Are tirzepatide side effects worse during dose escalation? Yes. Side effects peak during the first 2-3 weeks after each dose increase and then improve. This is true for both tirzepatide and semaglutide. Slower titration (staying at each dose for 6-8 weeks instead of 4 weeks) reduces peak side effect intensity.

Can I take anti-nausea medication with tirzepatide or semaglutide? Yes. Ondansetron (Zofran), metoclopramide (Reglan), and promethazine (Phenergan) are commonly prescribed for GLP-1-induced nausea. Over-the-counter options include ginger, vitamin B6, and Dramamine. There are no known dangerous interactions between these medications and GLP-1 drugs.

Does tirzepatide cause more serious side effects than semaglutide? No. Serious adverse events (hospitalization, life-threatening complications, death) occur at similar low rates for both drugs. Pancreatitis occurs in 0.1-0.2% of patients on either medication. Gallbladder disease occurs in 1.5-2.5% during rapid weight loss on either drug. Neither medication has a worse serious adverse event profile.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
9. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024.
10. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022.
11. Nauck MA et al. Cardiovascular Actions of GLP-1-Based Therapies: Mechanistic Insights. Cardiovascular Research. 2023.
12. Skov V et al. GLP1R Gene Polymorphisms and Gastrointestinal Side Effects in Patients Treated with Semaglutide. Diabetes Care. 2023.
13. Smits MM et al. Effect of tirzepatide on gastric emptying: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2023.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Zofran, Reglan, Phenergan, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.